Gina M. Mantia-Smaldone, MD
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase Cancer Center East Norriton-Hospital Outpatient Center
2701 Dekalb Pike
East Norriton, PA 19401
Assistant Professor, Department of Surgical Oncology
Specialties
Treatment Focus
Minimally invasive surgery (laparoscopy and robotic surgery); endometrial cancer and hyperplasia; cervical cancer and dysplasia; vulvar cancer and dysplasia; vaginal cancer and dysplasia; gestational trophoblastic disease; surgical management of pelvic masses
Research Program
Treatment Philosophy
I am excited to be a part of the gynecologic cancer patient care team at Fox Chase Cancer Center. I chose to work at Fox Chase to provide comprehensive, cutting-edge oncologic care by translating advances in research directly into my clinical practice.
As a gynecologic oncologist, I specialize in the surgical and medical management of tumors of the uterus, cervix, ovary, fallopian tube, vulva and vagina. I have extensive experience with complex open, laparoscopic and robotic surgery, which allows me to tailor a surgical plan based upon a patient’s needs and preferences. I also have expertise in administering intravenous and intraperitoneal chemotherapy for gynecologic malignancies. As a member of the multidisciplinary gynecologic cancer patient care team, I work closely with my colleagues in medical and radiation oncology to develop a comprehensive treatment plan that offers the best chance of cure for each patient.
I appreciate the challenges and commitment necessary to care for cancer patients. I understand that a cancer diagnosis can be overwhelming for patients and their families, and I always treat patients how I would want my family members to be treated: with honesty and compassion. I devote the time necessary to educate my patients on their options so they are best able to make an informed decision about their treatment.
Professionally, my research interests focus on endometriosis-associated ovarian cancer and hereditary ovarian cancer, including those resulting from BRCA1 or 2 mutations. The abundant resources available at Fox Chase, as well as my research experiences during my postdoctoral fellowship at the Magee-Womens Research Institute and as a clinical fellow at the University of Pennsylvania allow for me to participate in translational research and investigate innovative therapies to improve the quality of life for women with gynecologic malignancies.
Educational Background
- Clinical Fellow, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2010-2013
- Fellow, Ovarian Cancer Immunology, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, 2008-2010
- Resident, Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 2004-2008
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY, 2004
- BA, Biochemistry and Molecular Biology, Boston University, Boston, MA, 2000
Certifications
- American Board of Obstetrics and Gynecology – Obstetrics & Gynecology; Gynecologic Oncology
Memberships
- American Association for Cancer Research
- American College of Obstetrics and Gynecology
- NRG Oncology – Ovarian Cancer Core Committee; New Investigator Committee
- Society of Gynecologic Oncology, Registry Taskforce Committee
- Teal Tea Foundation, Advisory Board Member
- Alpha Omega Alpha
Diane Smith
Diane Smith
Diane Smith was 55 years old when she was diagnosed with colon cancer. After a local gastroenterologist initially diagnosed her with hemorrhoids, she sought a second opinion from a specialist at Fox Chase Cancer Center. Diane underwent a laparoscopic procedure that resulted in no scarring and allowed her to heal faster. After a week in the hospital, she returned home to finish her recovery. "I am now enjoying my time with friends, reading, walking in Pennypack Park, living a healthy lifestyle, and attending church regularly," she said. "I came back from cancer, and I thank God every day for directing me to Fox Chase."
Patti Rose
Patti Rose
At 36, Patti Rose, a wife and mother to seven children, was shocked to learn she had a rare form of breast cancer. Because her husband works in construction and had done several projects for Fox Chase Cancer Center, they knew right away Fox Chase was the right place for Patti's treatment. At Fox Chase, Patti underwent chemotherapy and radiation therapy, followed by a lumpectomy and additional surgery. The experience was extremely difficult, but Patti credits the staff at Fox Chase for giving her a positive outlook and helping her get through it. Today, she is cancer free and could not be more pleased with the treatment she received. "Fox Chase helped me to be positive. If I didn’t have that connection with doctors and nurses and even the security guard that I would talk to every time I was there, I think I would have felt more afraid," she said. "Knowing all those people were praying for me, thinking of me, and trying to get me through it made me feel like I could overcome it."
Jennifer Gilbert
Jennifer Gilbert
Jennifer Gilbert was 35 years old when she was diagnosed with cervical cancer. She was referred to Fox Chase Cancer Center for treatment, and she soon underwent surgery, and chemotherapy and radiation treatment. An exercise enthusiast, Jennifer started to experience severe swelling in my legs and was diagnosed with lymphedema, and rec eived therapy and underwent plastic and reconstructive surgery at Fox Chase. The surgeries worked, and today she is married with two adopted children.
Research Program
Research Interests
- Fertility and gynecologic cancers
- Endometriosis-related ovarian cancer
- Hereditary ovarian cancer
- Immunotherapy and ovarian cancer
Selected Publications
Cripe JC, Handorf E, Brown JL, Woodman S, Rubin SC, Jain A and Mantia-Smaldone GM. National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. Accepted for publication to International Journal of Gynecological Cancer, 3/10/17.
Andersen C, Sikora M, Boisen M, Ma T, Christie A, Tseng G, Park YS, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee A, Elishaev E, Edwards RP, and Oesterreich S. Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016. doi: 10.1158/1078-0432.CCR-16-1501. [Epub ahead of print]
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 Sep 6. pii: JCO681239. [Epub ahead of print]
Esselen KM, Cronin A, Bixel K, Bookman M, Burger RA, Cohn D, Cristea M, Griggs J, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis U, Niland J, Sun C, O’Malley DM, Wright A. Use of CA-125 Tests and CT Scans for Surveillance in Ovarian Cancer: Value-based Cancer Care? JAMA Oncol. 2016 Nov 1;2(11):1427-1433. doi: 10.1001/jamaoncol.2016.1842.
Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR. The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecol Oncol. 2016 Jun;141(3):434-9. doi: 10.1016/j.ygyno.2016.04.010.
Churilla T, Egleston B, Dong Y, Shaikh T, Murphy C, Mantia-Smaldone G, Chu C, Rubin S, Anderson P. Disparities in the management and outcome of cervical cancer in the United States according to health insurance status. Gynecol Oncol. 2016 Jun;141(3):516-23. doi: 10.1016/j.ygyno.2016.03.025.
Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome and beyond. Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019
Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes with PARP inhibition in BRCA1-deficient Ovarian cancer. Cancer Immunol Res. 2015 Jul 2. [Epub ahead of print]
Suryawanshi S, Budiu R, Elishaev E, Zhang L, Kim S, Tseng G, Mantia-Smaldone G, Ma T, Donnellan N, Lee T, Mansuria S, Edwards RP, Huang X and Vlad AM. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P and Adams SF. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficienct ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014 Jun;133(3):584-90. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
Mantia-Smaldone G, Bagley LJ, Kasner SE and Chu CS. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Gynecologic Oncology Case Reports. Volume 5, August 2013, 37-39. http://dx.doi.org/10.1016/j.gynor.2013.04.002.
Chiang CL, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torigian D, Levine B, Mick R, Kalos M, Czerniecki B, Powell D, and Coukos G. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clin Cancer Res. 2013 Jul 15 [Epub ahead of print]
Mantia-Smaldone GM and Chu CS. A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. BioDrugs. 2013 Oct;27(5):453-68. doi: 10.1007/s40259-013-0030-9.
Additional Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase Cancer Center East Norriton-Hospital Outpatient Center
2701 Dekalb Pike
East Norriton, PA 19401
Assistant Professor, Department of Surgical Oncology
Treatment Focus
Minimally invasive surgery (laparoscopy and robotic surgery); endometrial cancer and hyperplasia; cervical cancer and dysplasia; vulvar cancer and dysplasia; vaginal cancer and dysplasia; gestational trophoblastic disease; surgical management of pelvic masses
Research Program
Treatment Philosophy
I am excited to be a part of the gynecologic cancer patient care team at Fox Chase Cancer Center. I chose to work at Fox Chase to provide comprehensive, cutting-edge oncologic care by translating advances in research directly into my clinical practice.
As a gynecologic oncologist, I specialize in the surgical and medical management of tumors of the uterus, cervix, ovary, fallopian tube, vulva and vagina. I have extensive experience with complex open, laparoscopic and robotic surgery, which allows me to tailor a surgical plan based upon a patient’s needs and preferences. I also have expertise in administering intravenous and intraperitoneal chemotherapy for gynecologic malignancies. As a member of the multidisciplinary gynecologic cancer patient care team, I work closely with my colleagues in medical and radiation oncology to develop a comprehensive treatment plan that offers the best chance of cure for each patient.
I appreciate the challenges and commitment necessary to care for cancer patients. I understand that a cancer diagnosis can be overwhelming for patients and their families, and I always treat patients how I would want my family members to be treated: with honesty and compassion. I devote the time necessary to educate my patients on their options so they are best able to make an informed decision about their treatment.
Professionally, my research interests focus on endometriosis-associated ovarian cancer and hereditary ovarian cancer, including those resulting from BRCA1 or 2 mutations. The abundant resources available at Fox Chase, as well as my research experiences during my postdoctoral fellowship at the Magee-Womens Research Institute and as a clinical fellow at the University of Pennsylvania allow for me to participate in translational research and investigate innovative therapies to improve the quality of life for women with gynecologic malignancies.
Education
Educational Background
- Clinical Fellow, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2010-2013
- Fellow, Ovarian Cancer Immunology, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, 2008-2010
- Resident, Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 2004-2008
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY, 2004
- BA, Biochemistry and Molecular Biology, Boston University, Boston, MA, 2000
Certifications
- American Board of Obstetrics and Gynecology – Obstetrics & Gynecology; Gynecologic Oncology
Memberships
- American Association for Cancer Research
- American College of Obstetrics and Gynecology
- NRG Oncology – Ovarian Cancer Core Committee; New Investigator Committee
- Society of Gynecologic Oncology, Registry Taskforce Committee
- Teal Tea Foundation, Advisory Board Member
- Alpha Omega Alpha
Research Profile
Research Interests
- Fertility and gynecologic cancers
- Endometriosis-related ovarian cancer
- Hereditary ovarian cancer
- Immunotherapy and ovarian cancer
Publications
Selected Publications
Cripe JC, Handorf E, Brown JL, Woodman S, Rubin SC, Jain A and Mantia-Smaldone GM. National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. Accepted for publication to International Journal of Gynecological Cancer, 3/10/17.
Andersen C, Sikora M, Boisen M, Ma T, Christie A, Tseng G, Park YS, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee A, Elishaev E, Edwards RP, and Oesterreich S. Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016. doi: 10.1158/1078-0432.CCR-16-1501. [Epub ahead of print]
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 Sep 6. pii: JCO681239. [Epub ahead of print]
Esselen KM, Cronin A, Bixel K, Bookman M, Burger RA, Cohn D, Cristea M, Griggs J, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis U, Niland J, Sun C, O’Malley DM, Wright A. Use of CA-125 Tests and CT Scans for Surveillance in Ovarian Cancer: Value-based Cancer Care? JAMA Oncol. 2016 Nov 1;2(11):1427-1433. doi: 10.1001/jamaoncol.2016.1842.
Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR. The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecol Oncol. 2016 Jun;141(3):434-9. doi: 10.1016/j.ygyno.2016.04.010.
Churilla T, Egleston B, Dong Y, Shaikh T, Murphy C, Mantia-Smaldone G, Chu C, Rubin S, Anderson P. Disparities in the management and outcome of cervical cancer in the United States according to health insurance status. Gynecol Oncol. 2016 Jun;141(3):516-23. doi: 10.1016/j.ygyno.2016.03.025.
Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome and beyond. Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019
Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes with PARP inhibition in BRCA1-deficient Ovarian cancer. Cancer Immunol Res. 2015 Jul 2. [Epub ahead of print]
Suryawanshi S, Budiu R, Elishaev E, Zhang L, Kim S, Tseng G, Mantia-Smaldone G, Ma T, Donnellan N, Lee T, Mansuria S, Edwards RP, Huang X and Vlad AM. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P and Adams SF. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficienct ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014 Jun;133(3):584-90. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
Mantia-Smaldone G, Bagley LJ, Kasner SE and Chu CS. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Gynecologic Oncology Case Reports. Volume 5, August 2013, 37-39. http://dx.doi.org/10.1016/j.gynor.2013.04.002.
Chiang CL, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torigian D, Levine B, Mick R, Kalos M, Czerniecki B, Powell D, and Coukos G. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clin Cancer Res. 2013 Jul 15 [Epub ahead of print]
Mantia-Smaldone GM and Chu CS. A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. BioDrugs. 2013 Oct;27(5):453-68. doi: 10.1007/s40259-013-0030-9.
Additional Publications
Related Articles
35 PATIENT COMMENTS
-
5.0
July 24, 2019
Great service all around !
-
5.0
July 23, 2019
Can't say enough good things about Dr. Smaldone - she's great makes dealing with cancer so much easier.
-
4.5
July 19, 2019
My doctor was kind courteous and took time to listen to my questions. [...]
-
5.0
July 19, 2019
Dr Mantia-Smaldone is excellent!!!
-
5.0
July 18, 2019
Dr. Smaldone and her staff are the very best !
-
4.0
July 18, 2019
Dr. Gina Mantia Smaldone is an excellent Physician. She has made me feel confident about my health issue and I would not go to anyone but Dr. Gina Mantia Smaldone. I would recommend her to friends and family. I would also like to extend my thanks to Fox Chase Cancer for being a top notch institution. I trust them completely.
-
4.5
July 18, 2019
Dr. Mantia-Smaldone always makes me feel special.
-
5.0
June 30, 2019
Always an excellent experience with this provider... kind, genuine, knowledgeable and caring
-
5.0
June 25, 2019
dr mantia smaldone is a wonderful, compassionate and highly skilled doctor
-
5.0
June 25, 2019
REPCTIONIST WAS AWESOME, FRIENDLY AND FUNNY. DR MANTIA- SMALDONE IS THE BEST, NOT ONLY AS A DOCTOR BUT ALSO AS A PERSON. NURSES AND OTHER STAFF MEMBERS ARE ALWAYS GREAT
-
5.0
June 20, 2019
Dr. Gina Mantia Smaldone is an excellent doctor and I'm very confident in the care I receive.
-
5.0
May 21, 2019
Very satisfied with Dr. Smaldone and all I come in contact with.
-
5.0
April 30, 2019
I have the highest respect for Dr. Gina Mantia-Smalldone; She's Outstanding! [...]
-
5.0
April 23, 2019
good experience
-
5.0
April 21, 2019
Dr. Gina Mantia-Smaldone is a VERY VERY good doctor as well as having a wonderful bedside manner. She is helpful and caring - she is a true doctor and very intelligent & uses her intelligence for other people's good. I'm so thankful for her. She puts her interests aside to help people like me. We need more doctors like her. She's definitely an asset to your facility. I'm forever thankful to her.
-
4.0
April 03, 2019
I like the provider and the staff in the office. [...]
-
5.0
March 22, 2019
Dr. Gina Mantia-Smaldone is THE BEST doctor I have ever had. She is kind, caring, compassionate and definitely knows her stuff! I am grateful for her. She is awesome and so is her staff & CRN staff. Love FCCC!!!
-
5.0
March 21, 2019
I love Dr Smaldone and her nurse. I haven't been to her office in 4 years. and they remembered me and my story. They are amazing! They sat and talked to me and listened to everything.
-
5.0
March 19, 2019
I would recommend Dr. Mantia-Smaldone and Fox Chase in a heartbeat.
-
5.0
March 17, 2019
I liked this doctor so much that I am switching to her.
LOAD MORE